VOYAGE 1: Moderate to Severe PsO | TREMFYA® (guselkumab) HCP
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100 - JDDonline - Journal of Drugs in Dermatology
Access to Biologics in Argentina: Rethinking Time to PASI 90 | International Psoriasis Council
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials -
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
PASI 75, PASI 90, and PASI 100 response by baseline psoriasis severity... | Download Scientific Diagram
Figure 1 | Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses | SpringerLink
Evolution of psoriasis endpoint use - IQVIA
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
NNTs show once-unimaginable psoriasis outcomes now readily attainable | MDedge Rheumatology
Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink
Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study – JCAD | The Journal of Clinical
Plaque Psoriasis Skin Clearance | COSENTYX® (secukinumab)
Skin Clearance | Efficacy | RINVOQ® (upadacitinib)
PASI 90 / 100 , DLQI 0 / 1 , and IL-17 Receptor / Cytokine : Does it Make a Difference and Are We Ambitious Enough ? | Semantic Scholar
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study* - Reich - 2021 - British Journal of Dermatology - Wiley Online Library
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial* - Augustin -
Results for Cosentyx vs. Stelara Announced in PASI 90 Endpoint - MPR
Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) | HTML | Acta Dermato-Venereologica
